title: Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins.
abstract: Osteoporosis is associated with both atherosclerosis and vascular calcification. No mechanism yet explains the parallel progression of these diseases. Here, we demonstrate that osteoclasts (OCL) depend on lipoproteins to modulate cellular cholesterol levels and that this controls OCL formation and survival. Removal of cholesterol in OCL via high-density lipoprotein or cyclodextrin treatment dose-dependently induced apoptosis, with actin disruption, nuclear condensation and caspase-3 activation. One mechanism linked to the induction of OCL apoptosis was the cell-type-specific failure to induce HMG-CoA reductase mRNA expression, suggesting an absence of feedback regulation of de novo cholesterol biosynthesis. Furthermore, cyclodextrin treatment substantially suppressed essential M-CSF and RANKL-induced survival signaling pathways via Akt, mTOR and S6K. Consistent with these findings, cholesterol delivery via low-density lipoprotein (LDL) significantly increased OCL viability. Interestingly, OCLs from the LDL receptor (LDLR)-/- mouse exhibited reduced size and lifespan in vitro. Remarkably, LDLR+/+ OCL in lipoprotein-deficient medium phenocopied LDLR-/- OCL, while fusion and spreading of LDLR-/- OCL was rescued when cholesterol was chemically delivered during differentiation. With hyperlipidemia being associated with disease of the vascular system and bone, these findings provide novel insights into the selective lipoprotein and cholesterol dependency of the bone resorbing cell. Cell Death and Differentiation (2004) 11, S108-S118. doi:10.1038/sj.cdd.4401399 Published online 12 March 2004
authors.affiliation: Molecular Endocrinology & Bone Biology, Merck & Co., Inc., West Point, PA 19486, USA.
authors.forename: E
authors.initials: E
authors.lastname: Luegmayr
authors.forename: H
authors.initials: H
authors.lastname: Glantschnig
authors.forename: G A
authors.initials: GA
authors.lastname: Wesolowski
authors.forename: M A
authors.initials: MA
authors.lastname: Gentile
authors.forename: J E
authors.initials: JE
authors.lastname: Fisher
authors.forename: G A
authors.initials: GA
authors.lastname: Rodan
authors.forename: A A
authors.initials: AA
authors.lastname: Reszka
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000378:metabolism / Q000494:pharmacology*; D002117:Calcitriol / Q000494:pharmacology; D020169:Caspases / Q000378:metabolism; D022461:Caveolins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002784:Cholesterol / Q000172:deficiency / Q000378:metabolism* / Q000494:pharmacology; D008078:Cholesterol, LDL / Q000378:metabolism* / Q000494:pharmacology; D008075:Lipoproteins, HDL / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D041681:NIH 3T3 Cells; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D047392:beta-Cyclodextrins / Q000494:pharmacology
chemical_list: D016632:Apolipoprotein A-I; D022461:Caveolins; D008078:Cholesterol, LDL; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D047392:beta-Cyclodextrins; D002784:Cholesterol; D020169:Caspases; D002117:Calcitriol